Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Palbociclib + Endocrine Therapy in Early Stage HR+/HER2- Breast Cancer
NCT05069038Phase 2Active, not recruiting
- Sponsor
- University of Nebraska
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in breast cancer, sponsored by University of Nebraska. Started Mar 2022; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05069038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069038.